[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Breast cancer,Brain metastasis,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. Hamilton<\/b><sup>1<\/sup>, S.-B. Kim<sup>2<\/sup>, N. U. Lin<sup>3<\/sup>, A. Awada<sup>4<\/sup>, E. Ciruelos Gil<sup>5<\/sup>, A. Di Sanzo<sup>6<\/sup>, B. Piza Vallespir<sup>6<\/sup>, K. Puyana Theall<sup>7<\/sup>, N. Ibrahim<sup>8<\/sup>; <br\/><sup>1<\/sup>Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN, <sup>2<\/sup>Asan Medical Center, Seoul, Korea, Republic of, <sup>3<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>4<\/sup>Jules Bordet Cancer, Institute Brussels, Belgium, <sup>5<\/sup>Hospital Universitario 12 de octubre, Madrid, Spain, <sup>6<\/sup>Menarini Group, Florence, Italy, <sup>7<\/sup>Stemline Therapeutics\/Menarini Group, New York, NY, <sup>8<\/sup>MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"4a8fce1b-092c-4289-86e9-d1333cec8b2f","ControlNumber":"10315","DisclosureBlock":"<b>&nbsp;E. Hamilton, <\/b> <br><b>AstraZeneca<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Genentech\/Roche<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Lilly<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Daiichi Sankyo<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Mersana<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Novartis<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Pfizer<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Ellipses Pharma<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Olema Pharmaceuticals<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Stemline Therapeutics<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Orum Therapeutics<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Accutar Biotechnology<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Gilead Sciences<\/b> Other, Consulting or Advisory Role\u000d\u000aResearch Funding. <br><b>Greenwich LifeSciences<\/b> Other, Consulting or Advisory Role:\u000d\u000a\u000d\u000a. <br><b>Tubulis GmbH<\/b> Other, Consulting or Advisory Role:\u000d\u000a\u000d\u000a. <br><b>Verascity Science<\/b> Other, Consulting or Advisory Role:\u000d\u000a\u000d\u000a. <br><b>Theratechnologies<\/b> Other, Consulting or Advisory Role:\u000d\u000a\u000d\u000a. <br><b>Entos<\/b> Other, Consulting or Advisory Role:\u000d\u000a\u000d\u000a. <br><b>Fosun Pharma<\/b> Other, Consulting or Advisory Role:\u000d\u000a\u000d\u000a. <br><b>Jazz Pharmaceuticals<\/b> Other, Consulting or Advisory Role:\u000d\u000a\u000d\u000a. <br><b>S. Kim, <\/b> <br><b>Lilly<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca<\/b> Other, Consulting or Advisory Role. <br><b>DAEHWA Pharmaceutical<\/b> Stock, Consulting or Advisory Role. <br><b>ISU Abxis<\/b> Other, Consulting or Advisory Role. <br><b>BeiGene<\/b> Other, Consulting or Advisory Role. <br><b>Daiichi Sankyo\/Astra Zeneca<\/b> Other, Consulting or Advisory Role. <br><b>OBI Pharma<\/b> Other, Consulting or Advisory Role. <br><b>Ensol Biosciences<\/b> Other, Consulting or Advisory Role. <br><b>Genopeaks<\/b> Stock. <br><b>LegoChem Biosciences<\/b> Other, Honoraria. <br><b>Genzyme<\/b> Other, Research Funding. <br><b>N. U. Lin, <\/b> <br><b>Artera<\/b> Stock, Consulting or Advisory Role. <br><b>Pfizer<\/b> Consulting or Advisory Role and Research Funding. <br><b>Seagen<\/b> Other, Consulting or Advisory Role and Research Funding. <br><b>Olema Pharmaceuticals<\/b> Other, Consulting or Advisory Role and Research Funding. <br><b>Puma Biotechnology<\/b> Other, Consulting or Advisory Role. <br><b>Daiichi Sankyo<\/b> Other, Consulting or Advisory Role. <br><b>Denali Therapeutics<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca<\/b> Other, Consulting or Advisory Role. <br><b>Prelude Therapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Voyager Therapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Affinia Therapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Aleta Biotherapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Johnson & Johnson\/Janssen<\/b> Other, Consulting or Advisory Role. <br><b>Blueprint Medicines<\/b> Other, Consulting or Advisory Role. <br><b>Genentech<\/b> Research Funding. <br><b>Seagen<\/b> Other, Research Funding. <br><b>Merck<\/b> Other, Research Funding. <br><b>Zion Pharma<\/b> Other, Research Funding. <br><b>A. Awada, <\/b> <br><b>Roche<\/b> Other, Consulting or Advisory Role. <br><b>Lilly<\/b> Other, Consulting or Advisory Role. <br><b>Amgen<\/b> Other, Consulting or Advisory Role. <br><b>Eisai<\/b> Other, Consulting or Advisory Role. <br><b>Bristol-Myers Squibb<\/b> Other, Consulting or Advisory Role. <br><b>Pfizer<\/b> Other, Consulting or Advisory Role. <br><b>Novartis<\/b> Other, Consulting or Advisory Role. <br><b>MSD<\/b> Other, Consulting or Advisory Role. <br><b>Genomic Health<\/b> Other, Consulting or Advisory Role. <br><b>Ipsen<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca<\/b> Other, Consulting or Advisory Role. <br><b>Bayer<\/b> Other, Consulting or Advisory Role. <br><b>LEO Pharma<\/b> Other, Consulting or Advisory Role. <br><b>Merck Serono<\/b> Other, Consulting or Advisory Role. <br><b>Daiichi Sankyo\/Lilly<\/b> Other, Consulting or Advisory Role. <br><b>Pierre Fabre<\/b> Other, Consulting or Advisory Role. <br><b>Seagen<\/b> Other, Consulting or Advisory Role. <br><b>Hengrui Therapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Innate Pharma<\/b> Other, Consulting or Advisory Role.<br><b>E. Ciruelos Gil, <\/b> None.&nbsp;<br><b>A. Di Sanzo, <\/b> <br><b>Menarini-Stemline<\/b> Employment. <br><b>B. Piza Vallespir, <\/b> <br><b>Menarini-Stemline<\/b> Employment. <br><b>K. Puyana Theall, <\/b> <br><b>Menarini-Stemline<\/b> Employment.<br><b>N. Ibrahim, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11600","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT074","PresenterBiography":null,"PresenterDisplayName":"Erika Hamilton, MD","PresenterKey":"1b1f7a70-bc51-43cd-b2eb-05a58b5cd39b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT074. ELECTRA: An open-label, multicenter, phase 1b\/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"ELECTRA: An open-label, multicenter, phase 1b\/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Breast cancer,Estrogen receptor,Targeted therapy,Ubiquitination,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. M. Layman<\/b><sup>1<\/sup>, M. R. Patel<sup>2<\/sup>, D. Cosgrove<sup>3<\/sup>, M. Danso<sup>4<\/sup>, N. Mota<sup>5<\/sup>, M. E. Zettler<sup>5<\/sup>, K. C. Pehlivan<sup>5<\/sup>, E. Hamilton<sup>6<\/sup>; <br\/><sup>1<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL, <sup>3<\/sup>Northwest Cancer Specialists, Vancouver, WA, <sup>4<\/sup>Virginia Oncology Associates, Norfolk, VA, <sup>5<\/sup>Accutar Biotechnology Inc., Cranbury, NJ, <sup>6<\/sup>Sarah Cannon Cancer Institute, Nashville, TN","CSlideId":"","ControlKey":"367c4db6-08db-403d-831e-72c8e31a1ef2","ControlNumber":"9803","DisclosureBlock":"<b>&nbsp;R. M. Layman, <\/b> <br><b>Accutar Biotechnology, Inc., Pfizer, Puma,, Zentalis, Arvinas<\/b> Other, Research Funding to my Institution. <br><b>Eli Lilly, Novartis, Celucity<\/b> Other, Research Funding to my Institution and Advisory Board\/Consulting. <br><b>Gilead Sciences, Inc., Biotheryx<\/b> Other, Advisory Board\/Consulting. <br><b>M. R. Patel, <\/b> <br><b>ION Pharma<\/b> Other, Leadership. <br><b>Janssen Oncology<\/b> Other, Honoraria. <br><b>Accutar Biotechnology Inc., Daiichi Sankyo, Nurix, Olema Pharmaceuticals<\/b> Other, Consulting or Advisory Role. <br><b>Accutar Biotechnology Inc., Acerta Pharma, Adagene, ADC Therapeutics, Agenus, Aileron Therapeutics, Artios, Astellas, AstraZeneca, BioNTech AG, Boehringer Ingelheim, Black Diamond Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Blueprint Pharmaceuticals, Bayer, Bicycle Therapeutics, BioTheryX, Compugen, Cullinan Oncology, Celgene, CicloMed, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo, Lilly, Erasca, Inc.<\/b> Other, Research Funding to Institution. <br><b>Evelo Therapeutics, Genentech\/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, IgM Biosciences, Immunogen, Immune-Onc Therapeutics, Immunitas<\/b> Other, Research Funding to Institution. <br><b>Jazz Pharmaceuticals, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, Mabspace, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, NGM Biopharmaceuticals<\/b> Other, Research Funding to Institution. <br><b>Novartis, Nurix, Olema, ORIC Pharmaceuticals, Pionyr, PureTech, Pfizer, Prelude Therapeutics,  Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Step Pharma, Samumed, Silicon Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Seven and Eight Biopharmaceuticals, Syndax, Synthorx, Taiho Pharmaceutical, Tesaro, TopAlliance BioSciences Inc, Treadwell, TeneoBio, Treadwell Therapeutics, Xencor, Vigeo, Zymeworks<\/b> Other, Research Funding to Institution.<br><b>D. Cosgrove, <\/b> None.&nbsp;<br><b>M. Danso, <\/b> <br><b>Novartis, AstraZeneca<\/b> Other, Advisory Board. <br><b>N. Mota, <\/b> <br><b>Accutar Biotechnology Inc.<\/b> Employment. <br><b>M. E. Zettler, <\/b> <br><b>Accutar Biotechnology Inc.<\/b> Employment. <br><b>K. C. Pehlivan, <\/b> <br><b>Accutar Biotechnology Inc.<\/b> Employment. <br><b>E. Hamilton, <\/b> <br><b>Abbvie, Acerta Pharma, Accutar Biotechnology Inc., ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond<\/b> Other, Research Funding to Institution. <br><b>Bliss BioPharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis,\u0009Compugen, Context Therapeutics, Cullinan, Curis,\u0009CytomX, Daiichi Sankyo, Dana Farber Cancer Inst<\/b> Other, Research Funding to Institution. <br><b>Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, FujiFilm,\u0009G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma<\/b> Other, Research Funding to Institution. <br><b>Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences<\/b> Other, Research Funding to Institution. <br><b>Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine<\/b> Other, Research Funding to Institution. <br><b>Rgenix, Roche\/Genentech, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Verastem, Zenith Epigenetics,\u0009Zymeworks<\/b> Other, Research Funding to Institution. <br><b>AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Gilead Sciences, Greenwich LifeSciences, Janssen, Jazz Pharmaceuticals, Lilly, Loxo, Medical Pharma Services, Mersana, Novartis, Olema Pharmaceuticals<\/b> Other, Consulting\/Advisory Role (All Payments to Institution). <br><b>Orum Therapeutics, Pfizer, Relay Therapeutics, Roche\/Genentech, SeaGen, Stemline Therapeutics, Theratechnologies, Tubulis, Verascity Science, Zentalis Pharmaceuticals<\/b> Other, Consulting\/Advisory Role (All Payments to Institution).","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11601","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT075","PresenterBiography":null,"PresenterDisplayName":"Rachel Layman, MD","PresenterKey":"5c0b70a1-1c61-4207-a08b-865612d780d6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT075. A Phase 1 trial evaluating AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A Phase 1 trial evaluating AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"KRAS,T cell,Cytotoxic T cell,Therapeutic target,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Mitchell<sup>1<\/sup>, B. Khan<sup>1<\/sup>, F. Payumo<sup>1<\/sup>, E. Chiorean<sup>2<\/sup>, Z. Gahvari<sup>3<\/sup>, J. Hecht<sup>4<\/sup>, M. Hurwitz<sup>5<\/sup>, R. Leidner<sup>6<\/sup>, H.-J. Lenz<sup>7<\/sup>, M. Pelster<sup>8<\/sup>, S. Punekar<sup>9<\/sup>, A. Schoenfeld<sup>10<\/sup>, D. Zhao<sup>11<\/sup>, M. Vallaster<sup>1<\/sup>, <b>D. Nagorsen<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Affini-T Therapeutics, Inc., Watertown, MA, <sup>2<\/sup>Fred Hutchinson Cancer Research Center, Seattle, WA, <sup>3<\/sup>University of Wisconsin, Madison, WI, <sup>4<\/sup>University of California at Los Angeles, Los Angeles, CA, <sup>5<\/sup>Yale University, New Haven, CT, <sup>6<\/sup>Providence Cancer Institute, Portland, OR, <sup>7<\/sup>University of Southern California, Los Angeles, CA, <sup>8<\/sup>Sarah Cannon Research Institute,, Nashville, TN, <sup>9<\/sup>New York University, New York, NY, <sup>10<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>11<\/sup>MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"78076e84-3962-486c-9e01-25bfac44a99f","ControlNumber":"9661","DisclosureBlock":"<b>&nbsp;S. Mitchell, <\/b> <br><b>Affini-T Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>B. Khan, <\/b> <br><b>Affini-T Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>F. Payumo, <\/b> <br><b>Affini-T Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>E. Chiorean, <\/b> <br><b>Biosplice, Erasca, Novartis, Gilead, Mirati<\/b> Other, Grant\/Contract: Paid to institution. <br><b>Foundation, Axiom, G1 Therapeutic, Ipsen, Astellas, Pfizer, Merus, BMS, IGM Biosciences Regeneron, BPGBio<\/b> Other, Honoraria for Scientific Advisory Board.<br><b>Z. Gahvari, <\/b> None..<br><b>J. Hecht, <\/b> None..<br><b>M. Hurwitz, <\/b> None.&nbsp;<br><b>R. Leidner, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Travel. <br><b>Incyte<\/b> Grant\/Contract, Other, Data Safety Monitoring Board. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Merck<\/b> Other, Advisory Board. <br><b>Vir<\/b> Other, Advisory Board. <br><b>CDR Life<\/b> Other, Advisory Board. <br><b>H. Lenz, <\/b> <br><b>Fulgen<\/b> Stock Option, Advisory Board. <br><b>3T Bioscience<\/b> Stock Option, Scientific Advisory Board. <br><b>Merck<\/b> Other, Advisory Board. <br><b>Merck KG<\/b> Other, Advisory Board. <br><b>Bayer<\/b> Other, Advisory Board. <br><b>Abbvie<\/b> Other, Advisory Board. <br><b>BMS<\/b> Other, Advisory Board. <br><b>Affini T Therapeutics, Inc.<\/b> Other, Advisory Board. <br><b>BreakBio<\/b> Stock Option, Other, Founder. <br><b>M. Pelster, <\/b> <br><b>Actuate Therapeutics; Agenus; Arcus Biosciences; Astellas; BeiGene; BioNTech; Bristol-Myers Squibb; Codiak Biosciences; Compass Therapeutics; CytomX; Eisai; Elevation Oncology; Exelixis; Gilead; Hibe<\/b> Other, Contract; Paid to institution. <br><b>Arcus Biosciences; AstraZeneca; CytomX; Daiichi Sankyo; Elevation Oncology; EMD Serono; Ipsen Biopharmaceuticals; Jazz Pharmaceuticals; Pfizer; SeaGen<\/b> Other, Consulting; paid to institution.<br><b>S. Punekar, <\/b> None..<br><b>A. Schoenfeld, <\/b> None.&nbsp;<br><b>D. Zhao, <\/b> <br><b>Mirati Therapeutics<\/b> Grant\/Contract. <br><b>CARsgen<\/b> Grant\/Contract. <br><b>Affini-T Therapeutics, Inc.<\/b> Other, Advisory Board. <br><b>M. Vallaster, <\/b> <br><b>Affini-T Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>D. Nagorsen, <\/b> <br><b>Affini-T Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>Amgen<\/b> Stock, Other, Former employee.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11602","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT076","PresenterBiography":null,"PresenterDisplayName":"Dirk Nagorsen, MD","PresenterKey":"64b0c0d7-94f6-4c9c-bf0f-b9d36a140cde","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT076. AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8&#945;\/&#946; coreceptor; and a FAS41BB switch receptor in patients with advanced\/metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8&#945;\/&#946; coreceptor; and a FAS41BB switch receptor in patients with advanced\/metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Topoisomerase I inhibitor,CEACAM5,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>F. Meric-Bernstam<\/b><sup>1<\/sup>, C. A. Perez<sup>2<\/sup>, N. Lakhani<sup>3<\/sup>, M. Pelster<sup>4<\/sup>, J. Call<sup>5<\/sup>, S. McGoldrick<sup>6<\/sup>, T. Wang<sup>6<\/sup>, B. Demers<sup>7<\/sup>, A. Patnaik<sup>8<\/sup>; <br\/><sup>1<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, <sup>3<\/sup>START Midwest, Grand Rapids, MI, <sup>4<\/sup>SCRI Oncology Partners, Nashville, TN, <sup>5<\/sup>START Mountain Region, West Valley City, UT, <sup>6<\/sup>Seagen Inc., Bothell, WA, <sup>7<\/sup>Sanofi, Vitry-sur-Seine, France, <sup>8<\/sup>START San Antonio, San Antonio, TX","CSlideId":"","ControlKey":"87311568-88b0-463b-a950-c1a45b948050","ControlNumber":"9545","DisclosureBlock":"<b>&nbsp;F. Meric-Bernstam, <\/b> <br><b>AbbVie; Aduro BioTech Inc.; Alkermes; AstraZeneca; Calibr (a division of Scripps Research); Daiichi Sankyo Co. Ltd.; DebioPharm; Ecor1 Capital; eFFECTOR Therapeutics; F. Hoffman-La Roche Ltd.<\/b> Independent Contractor. <br><b>Genentech Inc.; GT Apeiron; Harbinger Health; IBM Watson; Incyte; Infinity Pharmaceuticals; Jackson Laboratory; Kolon Life Science; LegoChem Bio; Lengo Therapeutics; Menarini Group; OrigiMed<\/b> Independent Contractor, Advisory Board Membership. <br><b>PACT Pharma; Parexel International; Pfizer Inc.; Protai Bio Ltd.; Samsung Bioepis; Seagen Inc.; Tallac Therapeutics; Tyra Biosciences; Xencor; Zymeworks<\/b> Independent Contractor. <br><b>MD Anderson Cancer Center<\/b> Employment. <br><b>Aileron Therapeutics, Inc.; AstraZeneca; Bayer Healthcare Pharmaceutical; Calithera Biosciences Inc.; Curis Inc.; CytomX Therapeutics Inc.; Daiichi Sankyo Co. Ltd.; Debiopharm International<\/b> Grant\/Contract. <br><b>eFFECTOR Therapeutics; Genentech Inc.; Guardant Health Inc.; Klus Pharma; Takeda Pharmaceutical; Novartis; Puma Biotechnology Inc.; Taiho Pharmaceutical Co.<\/b> Grant\/Contract. <br><b>European Organisation for Research and Treatment of Cancer (EORTC); European Society for Medical Oncology (ESMO); Cholangiocarcinoma Foundation; Dava Oncology<\/b> Travel. <br><b>Black Diamond; Biovica; Eisai; FogPharma; Immunomedics; Inflection Biosciences; Karyopharm Therapeutics; Loxo Oncology; Mersana Therapeutics; OnCusp Therapeutics; Puma Biotechnology Inc.; Sanofi<\/b> Other, Advisory Board Membership. <br><b>Seagen Inc.; Silverback Therapeutics; Spectrum Pharmaceuticals; Theratechnologies; Zentalis<\/b> Other, Advisory Board Membership. <br><b>Dava Oncology<\/b> Other, Honoraria. <br><b>C. A. Perez, <\/b> <br><b>Beigene<\/b> Independent Contractor. <br><b>Accutar Biotech; Dracen Pharmaceuticals; Elpiscience Biopharmaceuticals; Elevation Oncology; Elucida Oncology; Genentech Inc.; Hyamab Inc.; Jazz Pharmaceuticals; Kinnate Biopharma; Kura Oncology<\/b> Grant\/Contract. <br><b>Mirati Therapeutics; Relay Therapeutics; Ribbon Therapeutics; Seagen Inc.; Tallac Therapeutics; Xilio Therapeutics; Zhuhai Yufan Biotechnologies Co. Ltd.<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Other, Advisory Board Membership. <br><b>N. Lakhani, <\/b> <br><b>Innovent Biologics<\/b> Independent Contractor. <br><b>Alexion; Alexo; Alpine Bio; Alpine Immune Sciences; Asana; Astellas; BeiGene; Biologics; Celgene; Cerulean; Constellation; Coordination Therapeutics; CytomX; Epizyme; Formation; Forty Seven; Genmab<\/b> Grant\/Contract. <br><b>Helsinn; Ikena; Incyte; InhibTx; Innovent; Jounce; Lam Therapeutics; Lilly; Livzon; Loso; Macrogenics; Merck; Mersana; Northern Bio; Odonate; Pfizer; Regeneron; Sapience; Seagen Inc.; Shattuck Labs<\/b> Grant\/Contract. <br><b>Symphogen; TaiRx; Tesaro<\/b> Grant\/Contract. <br><b>Ikena; Innovent Biologics; SK Life Sciences<\/b> Other, Advisory Board Membership. <br><b>Alkermes; Alpine Biosciences; ALX Therapeutics; Astellas; Celgene; Constellation Pharma; CytomX; Forty Seven; Gilead; GlaxoSmithKline; HeIsinn; InhibRx; Janssen; Jounce; KSQ Therapeutics; Loxo\/Lilly<\/b> Other, Invited Speaker. <br><b>Merck; Mersana Therapeutics; Northern Biologics; Pfizer; Regeneron; Repare Therapeutics; Sapience Therapeutics; Seagen Inc.; Samumed; Servier; Shattuck Labs; Symphogen; Tizona Therapeutics<\/b> Other, Invited Speaker. <br><b>M. Pelster, <\/b> <br><b>Arcus Biosciences; AstraZeneca; CytomX; Daiichi Sankyo; EMD Serono; Ipsen Biopharmaceuticals; Jazz Pharmaceuticals; Novartis; Pfizer; Seagen Inc.<\/b> Independent Contractor. <br><b>1200 Pharma; Acutate Therapeutics; Agenus; Arcus Biosciences; Astellas; BeiGene; BioNTech; Bristol-Myers Squibb; Codiak Biosciences; Compass Therapeutics; CytomX; Eisai; Elevation Oncology; Exelixis<\/b> Grant\/Contract. <br><b>Gilead; HiberCell; Immune-Onc Therapeutics; Leap Therapeutics; Novartis; OncXerna Therapeutics; Panbela Therapeutics; Revolution Medicines; Seagen Inc.; Surface Oncology; SQZ Biotechnologies<\/b> Grant\/Contract. <br><b>Tachyon Therapeutics; Translational Genomics; TransThera Sciences; ZielBio<\/b> Grant\/Contract.<br><b>J. Call, <\/b> None.&nbsp;<br><b>S. McGoldrick, <\/b> <br><b>Seagen Inc.<\/b> Employment, Stock. <br><b>T. Wang, <\/b> <br><b>Seagen Inc.<\/b> Employment, Stock. <br><b>B. Demers, <\/b> <br><b>Sanofi<\/b> Employment, Stock, Stock Option, Patent. <br><b>A. Patnaik, <\/b> <br><b>Bayer; Bristol Myers Squibb; Merck; Novartis; Roche\/Genentech; Seagen Inc.; Silverback Therapeutics; Shenzhen IONOVA Life Sciences., LTD.; Gilead; Daiichi Sankyo, Inc.; HalioDx; Janssen<\/b> Independent Contractor. <br><b>AbbVie; Arcus; Astellas; Bolt; Corvus; Daiichi Sankyo; Exelixis; Five Prime; Fochon Pharma; Forty Seven; Infinity Pharma; Ionova; Klus Pharma; Lilly; Livzon; Merck; Pieris Pharma; Gilead<\/b> Grant\/Contract. <br><b>Plexxikon; Pfizer; Sanofi; Seagen Inc.; Surface Oncology; Symphogen; Syndax; Tesaro; Upsher-Smith; Viego Therapeutics<\/b> Grant\/Contract. <br><b>Texas Society of Clinical Oncology<\/b> Other, Honoraria. <br><b>Shenzhen Ionova Life Scinces Co., LTD; Pionyr Immunotherapeutics Inc; Loxo Oncology Inc; Nektar Therapeutics; Alpine Immune Sciences Inc; Amgen; Institut de Recherches Internationales Servier;<\/b> Grant\/Contract. <br><b>1200 Pharma; Arcus Biosciences; Genentech; Aadi Biosciences; Prelude; KSQ Therapeutics; Carrick Therapeutics;<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11603","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT077","PresenterBiography":null,"PresenterDisplayName":"Funda Meric-Bernstam, MD","PresenterKey":"2117381e-3bd9-4428-b1dc-52a4e229b11c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT077. An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"EGFR,Antitumor activity,T cell,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. Mamdani<\/b><sup>1<\/sup>, J. R. Hecht<sup>2<\/sup>, R. E. Sanborn<sup>3<\/sup>, M. Palanca-Wessels<sup>4<\/sup>, M. Yan<sup>4<\/sup>, M. Gutierrez<sup>5<\/sup>, D. L. Bajor<sup>6<\/sup>; <br\/><sup>1<\/sup>Barbara Ann Karmanos Cancer Institute, Detroit, MI, <sup>2<\/sup>UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, <sup>3<\/sup>Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, <sup>4<\/sup>Seagen, Bothell, WA, <sup>5<\/sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, <sup>6<\/sup>Case Western Reserve University, Clevland, OH","CSlideId":"","ControlKey":"91501858-911a-4827-9de9-71bd768ea57c","ControlNumber":"9557","DisclosureBlock":"<b>&nbsp;H. Mamdani, <\/b> <br><b>Astrazeneca<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Genentech<\/b> Other, Advisory Board. <br><b>Daiichi Sankyo<\/b> Other, Advisory Board. <br><b>J. R. Hecht, <\/b> <br><b>Rafael; Actym; Trumvira; MBQPharma<\/b> Stock. <br><b>Galvanize; Astellas; IGMPharma; Taiho; Novartis; BMS; Exelixis; Deciphera<\/b> Other, Grant\/Contract Advisory. <br><b>A2; Agenus; Astellas; Bold; Camurus; CG; Crinetics; Exelixis; Gilead; Gritstone; Janssen; Lyell; Mirati; Neogene; NGM; Tizona; Cardiff; GSK<\/b> Other, Grant\/Contracts - Research to UCLA. <br><b>R. E. Sanborn, <\/b> <br><b>GlaxoSmithKline; AstraZeneca; Janssen Oncology; Macrogenics; Daiichi; Sanofi; BeiGene; Gilead; Regeneron; Targeted Oncology; G1 Therapeutics; GE HealthCare; Amgen; Lilly Oncology<\/b> Independent Contractor. <br><b>AstraZeneca; Merck<\/b> Grant\/Contract. <br><b>EMD Serono; Illumina; GameOn!; OncLive; Binay Foundation; APP Oncology; Masters in Thoracic Oncology Summit<\/b> Other, Honoraria. <br><b>M. Palanca-Wessels, <\/b> <br><b>Seagen<\/b> Employment, Stock. <br><b>M. Yan, <\/b> <br><b>Seagen<\/b> Employment. <br><b>M. Gutierrez, <\/b> <br><b>Guardant<\/b> Independent Contractor. <br><b>COTA\/OMI<\/b> Stock. <br><b>Acerta Pharma; Adlai Nortye; Arcus Biosciences; Array BioPharma; Bayer; Bellicum Pharmaceuticals; BMS; Boehringer Ingelheim; Celgene; Checkpoint Therapeutics; Compass Therapeutics<\/b> Grant\/Contract. <br><b>Constellation Pharmaceuticals; Cullinan Oncology; Cyteir; Daiichi Sankyo Company; Eisai; EMD Serono; EMD Serono; Erasca, Inc ; Fate Therapeutics; Georgetown Univ.; GlaxoSmithKline; GSB Pharma<\/b> Grant\/Contract. <br><b>Hackensack Meridian Health; Imugene; Incyte; Infinity Pharmaceuticals; ITeos Therapeutics; Janssen; Johnson & Johnson ; KSQ Therapeutics; MedImmune; Memorial Sloan-Kettering Cancer Center; Merck<\/b> Grant\/Contract. <br><b>Millennium; Mirati Therapeutics; Moderna Therapeutics; NextCure; NextCure; Nimbus Therapeutics; Pfizer; Pharmacyclics; Rapa Therapeutics; Regeneron; Roche\/Genentech; Sanofi; Seagen; Silenseed<\/b> Grant\/Contract. <br><b>Synlogic; Tesaro; Turning Point Therapeutics; Vedanta Biosciences ; VelosBio; Verastem; Vincerx Pharma<\/b> Grant\/Contract. <br><b>D. L. Bajor, <\/b> <br><b>Avoro Capital; BridgeBio Pharma; Cardinal Health; Tempus<\/b> Independent Contractor. <br><b>Apixigen; Bristol-Myers Squibb\/Celgene; Calithera Biosciences; GlaxoSmithKline; Rafael Pharma; Seagen; Tesaro<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11604","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT078","PresenterBiography":null,"PresenterDisplayName":"Natalie Pizzimenti","PresenterKey":"030b336a-1127-4334-8648-bfce2ff6df22","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT078. Phase 1 study of SGN-EGFRd2 in solid tumors (SGNEGFRd2-001)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 study of SGN-EGFRd2 in solid tumors (SGNEGFRd2-001)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Vaccines,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. Flatmark<\/b><sup>1<\/sup>, A. Torgunrud<sup>2<\/sup>, F. G. Karianne<sup>2<\/sup>, B. Davidson<sup>2<\/sup>, H. V. Juel<sup>2<\/sup>, N. Mensali<sup>2<\/sup>, C. Lund Andersen<sup>2<\/sup>, E. Inderberg<sup>2<\/sup>; <br\/><sup>1<\/sup>Norwegian Radium Hospital, Blommenholm, Norway, <sup>2<\/sup>Norwegian Radium Hospital, Oslo, Norway","CSlideId":"","ControlKey":"8eeff7f9-b782-4d6f-9152-f95bbf833916","ControlNumber":"10607","DisclosureBlock":"&nbsp;<b>K. Flatmark, <\/b> None..<br><b>A. Torgunrud, <\/b> None..<br><b>F. G. Karianne, <\/b> None..<br><b>B. Davidson, <\/b> None..<br><b>H. V. Juel, <\/b> None..<br><b>N. Mensali, <\/b> None..<br><b>C. Lund Andersen, <\/b> None..<br><b>E. Inderberg, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11605","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT079","PresenterBiography":null,"PresenterDisplayName":"Kjersti Flatmark, MD;PhD","PresenterKey":"4aebbd00-c0a1-484b-a722-a17a0ef4cb90","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT079. The Pseudovax trial: A novel peptide vaccine targeting mutated GNAS for pseudomyxoma peritonei","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The Pseudovax trial: A novel peptide vaccine targeting mutated GNAS for pseudomyxoma peritonei","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Cancer metabolism,Pancreatic cancer,Radiation therapy,Chemotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Kamgar<\/b><sup>1<\/sup>, H. Yar Khan<sup>2<\/sup>, A. Aboukameel<sup>2<\/sup>, S. F. Bannoura<sup>2<\/sup>, B. Y. Chung<sup>1<\/sup>, A. Szabo<sup>1<\/sup>, Y. Li<sup>2<\/sup>, M. Al Hallak<sup>2<\/sup>, P. A. Philip<sup>3<\/sup>, B. George<sup>1<\/sup>, K. K. Christians<sup>1<\/sup>, D. B. Evans<sup>1<\/sup>, S. Tsai<sup>4<\/sup>, B. Erickson<sup>1<\/sup>, J. M. Goldberg<sup>5<\/sup>, A. S. Azmi<sup>2<\/sup>, W. A. Hall<sup>1<\/sup>; <br\/><sup>1<\/sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2<\/sup>Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, <sup>3<\/sup>Henry Ford Cancer Institute, Detroit, MI, <sup>4<\/sup>Ohio State University, Colombus, OH, <sup>5<\/sup>Rafael Holdings Inc, Newark, NJ","CSlideId":"","ControlKey":"a172c3fd-9435-4b57-bcfe-4ab64c9f7f58","ControlNumber":"10858","DisclosureBlock":"<b>&nbsp;M. Kamgar, <\/b> <br><b>Cornerstone Pharmaceuticals<\/b> Other, Institutional research funding.<br><b>H. Yar Khan, <\/b> None..<br><b>A. Aboukameel, <\/b> None..<br><b>S. F. Bannoura, <\/b> None..<br><b>B. Y. Chung, <\/b> None..<br><b>A. Szabo, <\/b> None..<br><b>Y. Li, <\/b> None..<br><b>M. Al Hallak, <\/b> None..<br><b>P. A. Philip, <\/b> None.&nbsp;<br><b>B. George, <\/b> <br><b>Ipsen, Bristol Myers Squibb, Eisai, Boston  Scientific<\/b> Other, Consultant. <br><b>Taiho Oncology, Foundation Medicine, Roche\/Genentech, Pfizer,<\/b> Other, Consultant and Institutional research support. <br><b>Hoffman La Roche, Boehringer  Ingelheim, Faeth Therapeutics, Glyconex, Helix  Biopharma, Carsgen, Sirnamomics, Transcenta, Trishula  Therapeutics<\/b> Other, Institutional research support. <br><b>Toray, Hutchison  Medipharma, Mirati Therapeutics<\/b> Other, Research support. <br><b>XBiotech<\/b> Stock.<br><b>K. K. Christians, <\/b> None..<br><b>D. B. Evans, <\/b> None..<br><b>S. Tsai, <\/b> None..<br><b>B. Erickson, <\/b> None.&nbsp;<br><b>J. M. Goldberg, <\/b> <br><b>Rafael Holdings Inc<\/b> Employment. <br><b>A. S. Azmi, <\/b> <br><b>Colorado Chromatography,<\/b> Other, Funding. <br><b>Blackstone Therapeutics<\/b> Other, Funding. <br><b>GLG<\/b> Other, council member. <br><b>Guidepoint<\/b> Other, council member. <br><b>W. A. Hall, <\/b> <br><b>Elekta<\/b> Other, Research Funding. <br><b>Atkis Oncology<\/b> Other, Consultant.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11606","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT080","PresenterBiography":null,"PresenterDisplayName":"Mandana Kamgar, MD;MPH","PresenterKey":"d72a5e15-137f-470d-84e1-0d8d37dea29b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT080. A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Solid tumors,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. E. Dumbrava<\/b><sup>1<\/sup>, D. Olson<sup>2<\/sup>, S. Saibil<sup>3<\/sup>, D. P. Sohal<sup>4<\/sup>, S. Iqbal<sup>5<\/sup>, A. Urgelles<sup>6<\/sup>, M. Apostolopoulou<sup>6<\/sup>, A. Mueller<sup>6<\/sup>, K. Moss<sup>6<\/sup>, D. Adib<sup>6<\/sup>, B. Schlecter<sup>7<\/sup>; <br\/><sup>1<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>University of Chicago, Chicago, IL, <sup>3<\/sup>University Health Network Princess Margaret, Toronto, ON, Canada, <sup>4<\/sup>University of Cincinnati, Cincinnati, OH, <sup>5<\/sup>University of Southern California Health Sciences, Los Angeles, CA, <sup>6<\/sup>Triumvira Immunologics, Inc., Austin, TX, <sup>7<\/sup>Dana Farber Cancer Institute, Boston, MA","CSlideId":"","ControlKey":"dc9dbebe-3abe-4917-a52b-f249d652cc1a","ControlNumber":"10453","DisclosureBlock":"<b>&nbsp;E. E. Dumbrava, <\/b> <br><b>Bayer HealthCare Pharmaceuticals Inc, Immunocore LTD; Amgen; Aileron Therapeutics; Compugen Ltd; TRACON Pharmaceuticals Inc; Unum Therapeutics; Gilead Immunomedics; BOLT Therapeutics; Aprea Therapeut<\/b> Other, Research or grant funding. <br><b>BOLT Therapeutics; Mersana Therapeutics; Orum Therapeutics; Summit Therapeutics.&#8203;<\/b> Other, Advisory Board. <br><b>PMV Pharma<\/b> Other, Speaker. <br><b>ASCO; LFSA Association; Rain Oncology; Banner MD Anderson Cancer Center; Triumvira Immunologics.&#8203;<\/b> Travel, Other, Travel, accommodations and expenses. <br><b>D. Olson, <\/b> <br><b>GLG Consulting; Expert Insight; Iovance; Novartis; Obsidian.<\/b> Other, Consulting. <br><b>Iovance<\/b> Travel, Other, Travel, Lodging and food.<br><b>S. Saibil, <\/b> None..<br><b>D. P. Sohal, <\/b> None..<br><b>S. Iqbal, <\/b> None.&nbsp;<br><b>A. Urgelles, <\/b> <br><b>Triumvira Immunologics<\/b> Employment. <br><b>M. Apostolopoulou, <\/b> <br><b>Triumvira Immunologics<\/b> Employment. <br><b>A. Mueller, <\/b> <br><b>Triumvira Immunologics<\/b> Employment. <br><b>K. Moss, <\/b> <br><b>Triumvira Immunologics<\/b> Employment. <br><b>D. Adib, <\/b> <br><b>Triumvira Immunologics<\/b> Employment, Stock, Other, Leadership. <br><b>Epizyme, Ikena, Mythic, Eagle, OBI, RAIN<\/b> Other, RESEARCH FUNDING; CONSULTING OR ADVISORY ROLE; TRAVEL, ACCOMODATIONS, EXPENSES..<br><b>B. Schlecter, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11607","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT081","PresenterBiography":null,"PresenterDisplayName":"Ecaterina Dumbrava, MD","PresenterKey":"b5a9d78d-5dd5-487f-99fa-e3aa7f8f8a38","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT081. A phase 1\/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1\/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Colorectal cancer,T cell,KRAS,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"E. G. Chiorean<sup>1<\/sup>, A. Coveler<sup>1<\/sup>, R. Safyan<sup>1<\/sup>, S. Cohen<sup>1<\/sup>, S. Lee<sup>1<\/sup>, C. Yeung<sup>2<\/sup>, M. Redman<sup>2<\/sup>, T. Schmitt<sup>2<\/sup>, <b>A. Chapuis<\/b><sup>2<\/sup>, P. D. Greenberg<sup>2<\/sup>; <br\/><sup>1<\/sup>University of Washington, Seattle, WA, <sup>2<\/sup>Fred Hutchinson Cancer Center, Seattle, WA","CSlideId":"","ControlKey":"e92a015b-03fa-4b60-9298-495a6d96cd4d","ControlNumber":"10602","DisclosureBlock":"<b>&nbsp;E. G. Chiorean, <\/b> <br><b>Boehringer-Ingelheim, Biosplice, Erasca, Foundation, Axiom, Merck, Novartis, Gilead, Lonza, Mirati, AADi, G1 Pharmaceuticals, IGM Biosciences, Foundation, BPGBio<\/b> Grant\/Contract. <br><b>Astellas<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>AffiniT<\/b> Grant\/Contract. <br><b>Ipsen<\/b> Grant\/Contract. <br><b>Regeneron<\/b> Grant\/Contract. <br><b>Merus<\/b> Grant\/Contract, Travel. <br><b>A. Coveler, <\/b> <br><b>Astra-Zeneca<\/b> Grant\/Contract. <br><b>Actuate<\/b> Grant\/Contract. <br><b>SeaGen<\/b> Grant\/Contract. <br><b>R. Safyan, <\/b> <br><b>Replimune<\/b> Grant\/Contract. <br><b>Exelixis<\/b> Grant\/Contract. <br><b>Verastem<\/b> Grant\/Contract. <br><b>S. Cohen, <\/b> <br><b>Natera<\/b> Grant\/Contract. <br><b>Biomea<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract.<br><b>S. Lee, <\/b> None..<br><b>C. Yeung, <\/b> None..<br><b>M. Redman, <\/b> None.&nbsp;<br><b>T. Schmitt, <\/b> <br><b>AffiniT<\/b> Grant\/Contract. <br><b>A. Chapuis, <\/b> <br><b>AffiniT<\/b> Grant\/Contract. <br><b>P. D. Greenberg, <\/b> <br><b>AffiniT<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11608","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT082","PresenterBiography":null,"PresenterDisplayName":"Aude Chapuis, MD","PresenterKey":"1827409e-b34e-479f-a4ae-fb42ab36545e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT082. Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal and non-small cell lung cancers with KRAS G12V mutations","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal and non-small cell lung cancers with KRAS G12V mutations","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Pancreatic cancer,first-in-human,Monoclonal antibodies,Targeted therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. F. Batlle<sup>1<\/sup>, D. A. King<sup>2<\/sup>, <b>J. Kim<\/b><sup>3<\/sup>, S. Pradhan<sup>3<\/sup>, Y.-Y. Park<sup>4<\/sup>, K. Mandakhalikar<sup>3<\/sup>, W. Loh<sup>3<\/sup>; <br\/><sup>1<\/sup>Hospital Universitario La Paz, Madrid, Spain, <sup>2<\/sup>Northwell Health Cancer Institute, RJ Zuckerberg Cancer Center, Lake Success, NY, <sup>3<\/sup>Prestige Biopharma Limited, Singapore, Singapore, <sup>4<\/sup>Prestige BioPharma IDC Co., Ltd, Busan, Korea, Republic of","CSlideId":"","ControlKey":"94255663-0486-4631-b67f-5d189af56b55","ControlNumber":"9857","DisclosureBlock":"<b>&nbsp;J. F. Batlle, <\/b> <br><b>AMGEN<\/b> Grant\/Contract, Other, Advisory board expert testimony. <br><b>Roche<\/b> Other, Advisory board expert testimony. <br><b>Astra-Zeneca<\/b> Other, Advisory board expert testimony. <br><b>Viatris<\/b> Other, Advisory board expert testimony. <br><b>Prestige Biopharma Limited<\/b> Grant\/Contract. <br><b>D. A. King, <\/b> <br><b>Illumina<\/b> Stock. <br><b>Skysis<\/b> Other, Honorarium. <br><b>Ipsen<\/b> Other, Honorarium. <br><b>Omni Health<\/b> Other, Honorarium. <br><b>Prestige Biopharma Limited<\/b> Grant\/Contract. <br><b>J. Kim, <\/b> <br><b>Prestige Biopharma Limited<\/b> Employment. <br><b>S. Pradhan, <\/b> <br><b>Prestige Biopharma Limited<\/b> Employment. <br><b>Y. Park, <\/b> <br><b>Prestige BioPharma IDC Co., Ltd<\/b> Employment. <br><b>K. Mandakhalikar, <\/b> <br><b>Prestige Biopharma Limited<\/b> Employment. <br><b>W. Loh, <\/b> <br><b>Prestige Biopharma Limited<\/b> Employment.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11609","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT083","PresenterBiography":null,"PresenterDisplayName":"Jamie Kim, PharmD","PresenterKey":"4d4af128-8997-42b2-9c0b-2b3ac9a08d82","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT083. A first-in-human phase 1\/2a study of a novel anti-PAUF monoclonal antibody PBP1510 in patients with advanced\/metastatic pancreatic cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-human phase 1\/2a study of a novel anti-PAUF monoclonal antibody PBP1510 in patients with advanced\/metastatic pancreatic cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Nectin-4,LY4101174 (ETx-22),Advanced or Metastatic Urothelial Cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Rosenberg<\/b><sup>1<\/sup>, R. Sabatier<sup>2<\/sup>, A. Viceneux<sup>3<\/sup>, T. de La Motte Rouge<sup>4<\/sup>, S. Champiat<sup>5<\/sup>, L. Lebellec<sup>6<\/sup>, P. Barthlmy<sup>7<\/sup>, G. Sonpavde<sup>8<\/sup>, X. Gao<sup>9<\/sup>, S. Niglio<sup>10<\/sup>, T. Zhang<sup>11<\/sup>, C. Gedye<sup>12<\/sup>, M. Galsky<sup>13<\/sup>, M. Milowsky<sup>14<\/sup>, M. Reimers<sup>15<\/sup>, A. Weickhardt<sup>16<\/sup>, E. Grande<sup>17<\/sup>, D. E. Castellano<sup>18<\/sup>, M. Bilen<sup>19<\/sup>, A. Patnaik<sup>20<\/sup>, R. Zerbib<sup>21<\/sup>, M. Balbas<sup>22<\/sup>, X. Xu<sup>22<\/sup>, K. Aptaker<sup>22<\/sup>, A. V. Balar<sup>22<\/sup>, A. H. Awada<sup>23<\/sup>; <br\/><sup>1<\/sup>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, <sup>2<\/sup>Medical Oncology Department, Institute Paoli-Calmettes, Marseille, France, <sup>3<\/sup>Dpartement de Cancrologie mdicale, centre Lon-Brard, Lyon, France, <sup>4<\/sup>Medical Oncology Department, Centre Eugene Marquis, Rennes, France, <sup>5<\/sup>Gustave Roussy, Villejuif, France, <sup>6<\/sup>Medical Oncology Department, Centre Oscar Lambret, Lille, France, <sup>7<\/sup>Institut de Cancrologie Strasbourg Europe (ICANS), Strasbourg, France, <sup>8<\/sup>Division of Medical Oncology, Advent Health Cancer Institute, Orlando, FL, <sup>9<\/sup>Massachusetts General Hospital Cancer Center, Boston, MA, <sup>10<\/sup>New York University Grossman School of Medicine, New York, NY, <sup>11<\/sup>UT Southwestern Medical Center, Dallas, TX, <sup>12<\/sup>Icon Cancer Centre, Adelaide, SA, Australia, <sup>13<\/sup>Department of Genitourinary Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>14<\/sup>Department of Medicine, Division of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>15<\/sup>Department of Internal Medicine, Washington University in St Louis, St. Louis, MO, <sup>16<\/sup>Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, Australia, <sup>17<\/sup>MD Anderson Cancer Center Madrid, Madrid, Spain, <sup>18<\/sup>Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>19<\/sup>Winship Cancer Institute of Emory University, Hematology & Medical Oncology, Atlanta, GA, <sup>20<\/sup>START San Antonio, San Antonio, TX, <sup>21<\/sup>Emergence Therapeutics, Marseille, France, <sup>22<\/sup>Loxo@Lilly, Stamford, CT, <sup>23<\/sup>Medical Oncology Department, Jules Bordet Institute, Brussels, Belgium","CSlideId":"","ControlKey":"0cb255c7-1d7f-4d60-8afc-3580414865de","ControlNumber":"9721","DisclosureBlock":"<b>&nbsp;J. Rosenberg, <\/b> <br><b>Astellas; Seagen; Acrivon; AstraZeneca<\/b> Grant\/Contract, Other. <br><b>AstraZeneca; BMS; Astellas; Seagen; Hengrui; Century Therapeutics; Gilead; EMD Serono; Merck; IMVAX; Aadi Biosciences; Alligator; Tyra; Boehringer Ingelheim<\/b> Other, Consultant. <br><b>Pfizer; EMD Serono; Medscape; MJH Lifesciences<\/b> Other, Honoraria. <br><b>R. Sabatier, <\/b> <br><b>GSK; Eisai<\/b> Independent Contractor, Consultant. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>GSK; Novartis; MSD<\/b> Travel. <br><b>Novartis; Eisai; Clovis Oncology; GSK; Seagen<\/b> Other, Speakers' Bureau. <br><b>A. Viceneux, <\/b> <br><b>Astellas; Pfizer<\/b> Grant\/Contract. <br><b>MSD, Ipsen, Janssen, Bouchara Recordati<\/b> Travel. <br><b>T. de La Motte Rouge, <\/b> <br><b>AstraZeneca; Clovis Oncology; Gilead; GSK; MSD; Mylan; Pfizer; Roche; Sanofi; Seagen; Tesaro<\/b> Other, Advisory Board. <br><b>Novartis<\/b> Other, Invited Speaker. <br><b>AstraZeneca; GSK; MSD; Netris Pharma; Roche; Pfizer<\/b> Other, Local PI, Institutional. <br><b>MSD; Novartis; Pfizer<\/b> Grant\/Contract, Research Grant to Institution. <br><b>MSD<\/b> Other, Steering Committee Member. <br><b>S. Champiat, <\/b> <br><b>Amgen; Astellas; AstraZeneca; Bristol-Myers Squibb; Eisai; Genmab; Janssen; Merck KGaA; MSD; Novartis; Roche; Servier<\/b> Other, Speaking Engagement. <br><b>Abbvie; Amgen; Boehringer Ingelheim; Bolt Biotherapeutics; Centessa Pharmaceuticals; Cytovation; Eisai; GlaxoSmithKline; Imcheck Therapeutics; Immunocore; Molecular Partners Ag; MSD<\/b> Other, Principal Investigator of Clinical Trials. <br><b>Ose Immunotherapeutics; Pierre Fabre; Replimune; Roche; Sanofi Aventis; Seagen; Sotio A.S; Transgene<\/b> Other, Principal Investigator of Clinical Trials. <br><b>Alderaan Biotechnology; Amgen; AstraZeneca; Avacta; Beigene; BioNTech; Celanese; Domain Therapeutics; Ellipses Pharma; Genmab; Immunicom, Inc.; Mariana Oncology; Nanobiotix; Nextcure; Oncovita<\/b> Consulting or Advisory Board. <br><b>Pierre Fabre; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8<\/b> Travel, Travel and Congress. <br><b>L. Lebellec, <\/b> <br><b>Astellas Pharma<\/b> Other, Honoraria. <br><b>Pfizer; Eisai Europe; Bristol-Myers Squibb\/Pfizer<\/b> Travel. <br><b>P. Barthlmy, <\/b> <br><b>BMS; MSD; Astella Pharma; Janssen-Cilag; Pfizer; Merck KGaA; Novartis; Seagen; Ipsen; Gilead; Bayer<\/b> Other, Honoraria. <br><b>Ipsen; BMS; MSD Oncology; Pfizer; Janssen-Cilag; AstraZeneca; Amgen; Merck KGaA; Esai; Gilead; Bayer; AAA\/Endocyte\/Novartis<\/b> Other, Consulting or Advisory Role. <br><b>Ipsen<\/b> Grant\/Contract, Research Funding to Institution. <br><b>BMS; Pfizer; Janssen-Cilag; MSD; Ipsen; Merck\/Pfizer<\/b> Travel. <br><b>G. Sonpavde, <\/b> <br><b>BMS; Genentech; EMD Serono; Merck; AstraZeneca; Sanofi; Seattle Genetics\/Astellas; Exelixis; Janssen; Bicycle Therapeutics; Pfizer; Gilead; Scholar Rock; G1 Therapeutics<\/b> Other, Advisory Board. <br><b>Eli Lilly\/Loxo Oncology; Infinity Pharmaceuticals; Lucence Health; IMV; Vial; Syapse; Tempus; Ellipses Pharma; PrecisCa; Primum<\/b> Other, Advisory Board. <br><b>Suba Therapeutics; Syapse; Servier; Merck; Syncorp<\/b> Other, Consultant or Scientific Advisory Board (SAB). <br><b>Sanofi; AstraZeneca; Gilead; Helsinn; Lucence; BMS; EMD Serono; Jazz Therapeutics<\/b> Grant\/Contract, Other, Research Funding to Institution. <br><b>BIO  INFORMAO BRASILEIRA DE ONCOLOGIA Ltda; OLE Forum (Mexico); Seagen; Gilead; Natera; Exelixis; Janssen; Bayer; AVEO<\/b> Other, Speaker. <br><b>Mereo<\/b> Other, Data safety monitoring committee honorarium. <br><b>Myriad<\/b> Employment, Spouse employed by Myriad. <br><b>Uptodate; Practice Update; Onviv<\/b> Other, Writing or Editor fees. <br><b>X. Gao, <\/b> <br><b>Flare Therapeutics; Silverback Therapeutics; PureTech; Myovant Sciences; PATHAI; Loxo\/Lilly<\/b> Other, Consulting or Advisory Role. <br><b>Arvinas; Exelixis; Pfizer; Harpoon Therapeutics; Aprea Therapeutics; Takeda; Aravive; Merck; Poseida Therapeutics; TopAlliance BioSciences Inc., Novartis; Regeneron; Bayer; ALX Oncology; Nuvation Bio<\/b> Grant\/Contract, Research Funding to Institution. <br><b>Loxo\/Lilly<\/b> Grant\/Contract, Research Funding to Institution.<br><b>S. Niglio, <\/b> None.&nbsp;<br><b>T. Zhang, <\/b> <br><b>Capio BioSciences; Archimmune Therapeutics<\/b> Other, Leadership, An Immediate Family Member. <br><b>Capio BioSciences; Archimmune Therapeutics; Nanorobotics<\/b> Stock Option, Immediate Family Member. <br><b>MJH Life Sciences; Aptitude Health; Curio Science; Peerview; Clinical Care Options; Caris Life Sciences<\/b> Other, Honoraria. <br><b>Janssen; Exelixis; Pfizer; Bristol-Myers Squibb; Seattle Genetics; Eisai; Aravive; Bayer; Eli Lilly; AVEO; Merck; Sanofi\/Aventis; Novartis; Gilead Sciences; EMD Serono<\/b> Other, Consulting or Advisory Role. <br><b>Loxo\/Lilly; Tempus; Pfizer; ALX oncology; Exelixis<\/b> Grant\/Contract, Research Funding to Institution. <br><b>Circulating tumor cell novel capture by c-MET technology; Prochelators as Targeted Prodrugs for Prostate Cancer<\/b> Patent, Other Intellectual Property, Patents, Royalties, Other Intellectual Property to Institution. <br><b>Janssen<\/b> Travel. <br><b>ASCO; KCA; KidneyCan; Myrovlytis Trust<\/b> Other. <br><b>C. Gedye, <\/b> <br><b>Novotech; CADEX Genomics; BCAL Diagnostics<\/b> Other, Consulting or Advisory Role. <br><b>Bristol-Myers Squibb; Merck Sharp & Donne<\/b> Other, Consulting or Advisory Role, Recipient - Institution. <br><b>Limbic Oncology<\/b> Other, Speakers' Bureau, Recipient - Institution. <br><b>M. Galsky, <\/b> <br><b>Rappta Therapeutics<\/b> Stock. <br><b>Janssen; Merck; Bristol-Myers Squibb; Pfizer; EMD Serono; AstraZeneca; Seattle Genetics; Gilead; Abbvie; Bicycle Therapeutics; Daiichi Sankyo Europe GmbH; Curis<\/b> Other, Consulting\/Advisory Role. <br><b>Janssen Oncology; Dendreon; Novartis; Bristol-Myers Squibb; Merck; AstraZeneca; Genentech\/Roche;<\/b> Grant\/Contract, Research Funding to Institution. <br><b>METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792<\/b> Patent. <br><b>M. Milowsky, <\/b> <br><b>Pfizer; Merck; Gilead Sciences<\/b> Stock. <br><b>Loxo\/Lilly<\/b> Other, Consulting or Advisory Role. <br><b>Merck; Roche Genentech; Bristol-Myers Squibb; Mirati Therapeutics; Incyte; Seagen; GI Therapeutics; Alliance Foundation Trials; Alliance for Clinical Trials in Oncology; Clovis Oncology; Arvinas<\/b> Grant\/Contract, Research Funding to Institution. <br><b>ALX Oncology; Loxo\/Lilly; Hoosier Cancer Research Network; AstraZeneca\/MedImmune; Novartis; Acrivon Therapeutics; Astellas Pharma; Genentech; Accuray; Boehringer Ingelheim; Amgen<\/b> Grant\/Contract, Research Funding to Institution. <br><b>Constellation Pharmaceuticals; PCCTC; Bayer<\/b> Grant\/Contract, Research Funding to Institution. <br><b>Elsevier; Medscape; Research to Practice<\/b> Other. <br><b>M. Reimers, <\/b> <br><b>SUNA Urologic<\/b> Other, Honoraria. <br><b>Loxo; Pathos AI, Inc<\/b> Other, Consulting or Advisory Role. <br><b>FORMA Therapeutics; Amgen; Merck; Genentech; Lilly; BMS GmbH & Co. KG; Loxo; CRISPR Therapeutics; AstraZeneca; Eisai; Exelixis; Janssen; ProfoundBio;<\/b> Grant\/Contract, Research Funding to Institution. <br><b>A. Weickhardt, <\/b> <br><b>Ipsen; Pfizer; MSD; Merck; Astellas<\/b> Other, Honoraria. <br><b>Bayer; Ipsen; Janssen; MSD; Merck; Astellas<\/b> Other, Consulting. <br><b>Bayer<\/b> Travel. <br><b>E. Grande, <\/b> <br><b>MD ANDERSON CANCER CENTER MADRID<\/b> Employment. <br><b>AstraZeneca; Ipsen; Lexicon; Merck KGaA; MTEM\/Threshold\/Tersera; Nanostring Technologies; Pfizer; Roche<\/b> Grant\/Contract. <br><b>Abbott; Adium; Advanced Accelerator Applications; AMGEN; Angelini; Astellas; AstraZeneca; AVEO; Bayer; Blueprint; Bristol-Myers Squibb; Clovis-Oncology; Dr. Reddys; Eisai; Esteve; Eusa Pharma; GSK<\/b> Other, Honoraria for speaker engagements, advisory roles or funding of continuous medical education. <br><b>IPSEN; ITM-Radiopharma; Janssen; Lilly; Merck KGaA; MSD; Novartis; ONCODNA (Biosequence); Palex; Pfizer; Raffo; Roche; Tecnofarma; Thermo Fisher Scientific; Zodiac<\/b> Honoraria for speaker engagements, advisory roles or funding of continuous medical education. <br><b>D. E. Castellano, <\/b> <br><b>Pfizer, Novartis, Roche, BMS, Astellas, Janssen, MSD<\/b> Grant\/Contract. <br><b>Pfizer, Roche, Janssen, Novartis\/AAA, Ipsen<\/b> Travel. <br><b>M. Bilen, <\/b> <br><b>Exelixis; Bayer; BMS; Eisai; Pfizer; AstraZeneca; Janssen; Calithera Biosciences; Genomic Health; Nektar; EMD Serono; SeaGen; Sanofi<\/b> Other, Paid Consultant or Advisory Board Member. <br><b>Merck; Xencor; Bayer; Bristol-Myers Squibb; Genentech\/Roche; SeaGen; Incyte; Nektar; AstraZeneca; Tricon Pharmaceuticals; Genome & Company; AAA; Peloton Therapeutics; Pfizer<\/b> Grant\/Contract, Research Funding to Institution. <br><b>A. Patnaik, <\/b> <br><b>Texas Society of Clinical Oncology (TxSCO)<\/b> Other, Honoraria. <br><b>Genentech\/Roche; Merck; Bristol-Myers Squibb<\/b> Other, Consulting or Advisory Role, an Immediate Family Member. <br><b>Bayer; Novartis; Merck; Seattle Genetics; Silverback Therapeutics; Shenzen IONOVA Life Sciences Co., Ltd; Gilead; Daiichi Sankyo, Inc; HalioDx; Janssen<\/b> Consulting or Advisory Role. <br><b>Merck; Pfizer; Lilly; Plexxikon; Corvus Pharmaceuticals; Tesaro; Abbvie; Forty Seven; Five Prime Therapeutics; Infinity Pharmaceuticals; Pieris Pharamceuticals; Surface Oncology; Livson<\/b> Grant\/Contract, Research Funding to Institution. <br><b>Vigeo Therapeutics; Astella Pharma; Klus Pharma; Symphogen; Syndax; Arcus; Fochon; Upsher-Smith; Exelixis; Seattle Genetics; Bolt; Ionova; Daiichi Sankyo; Sanofi; Gilead Sciences; Daiichi-Sankyo<\/b> Grant\/Contract, Research Funding to Institution. <br><b>Seagen Inc.; Shenzhen Ionova Life Science Co. Ltd; Pionyr Immunotherapeutics, Inc.; Loxo Oncology, Inc. on behalf of Eli Lilly and Company; Nektar Therapeutics; Alpine Immune Sciences, Inc.; Amgen<\/b> Grant\/Contract, Research Funding to Institution. <br><b>Institut de Recherches Internationales Servier (I.R.I.S); 1200 Pharma; Arcus Biosciences; Genentech; Aadi Bioscience; Prelude; KSQ Therapeutics; Carrick Therapeutics;<\/b> Grant\/Contract, Research Funding to Institution. <br><b>R. Zerbib, <\/b> <br><b>Emergence Therapeutics<\/b> Independent Contractor. <br><b>M. Balbas, <\/b> <br><b>Loxo@Lilly<\/b> Employment. <br><b>Eli Lilly and Company<\/b> Stock. <br><b>X. Xu, <\/b> <br><b>Loxo@Lilly<\/b> Employment. <br><b>Eli Lilly and Company<\/b> Stock. <br><b>K. Aptaker, <\/b> <br><b>Loxo@Lilly<\/b> Employment. <br><b>Eli Lilly and Company<\/b> Stock. <br><b>A. V. Balar, <\/b> <br><b>Loxo@Lilly<\/b> Employment. <br><b>Eli Lilly and Company<\/b> Stock. <br><b>A. H. Awada, <\/b> <br><b>Amgen; AstraZeneca; Bayer; Daiichi; Eisai; Genomic Health; Hengrui; Innate; Ipsen; Leo Pharma; Lilly; Merck; MSD; Novartis; Pfizer; Seattle Genetics; Menarini<\/b> Other, Advisory Role. <br><b>Amgen; AstraZeneca; Bayer; Daiichi; Eisai; Genomic Health; Ipsen; Leo Pharma; Lilly; Merck; MSD; Novartis; Pfizer; Seattle Genetics<\/b> Other, Speaker fees. <br><b>BMS; Roche<\/b> Grant\/Contract, Research Grants to Institute.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11610","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT084","PresenterBiography":null,"PresenterDisplayName":"Jonathan Rosenberg, MD","PresenterKey":"895a524f-5f0e-482e-bc88-323a5c52339d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT084. A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Bladder cancer,Androgen deprivation therapy,degarelix,urothelial cell carcinoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Araoye<sup>1<\/sup>, A. Mega<sup>1<\/sup>, G. G. Lagos<sup>1<\/sup>, B. Carneiro<sup>2<\/sup>, S. Khaleel<sup>1<\/sup>, D. Golijanin<sup>1<\/sup>, <b>S. L. HOLDER<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, Providence, RI, <sup>2<\/sup>Legorreta Cancer Center at Brown University  and Lifespan Cancer Institute, Providence, RI","CSlideId":"","ControlKey":"4ed6c37c-21ab-49eb-8258-9dbaf9478997","ControlNumber":"10723","DisclosureBlock":"&nbsp;<b>M. Araoye, <\/b> None.&nbsp;<br><b>A. Mega, <\/b> <br><b>Bristol Meyers Squibb<\/b> Other, Consulting, speaker.<br><b>G. G. Lagos, <\/b> None..<br><b>B. Carneiro, <\/b> None..<br><b>S. Khaleel, <\/b> None..<br><b>D. Golijanin, <\/b> None..<br><b>S. L. Holder, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11611","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT085","PresenterBiography":null,"PresenterDisplayName":"Sheldon Holder, MD;PhD","PresenterKey":"ecab730c-8f52-4d58-bd61-54725c83f3ba","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT085. Targeting androgen signaling in urothelial carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting androgen signaling in urothelial carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Cancer immunotherapy,CD40,Bladder cancer,Antibody engineering,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. C. Osorio<\/b><sup>1<\/sup>, M. Alam<sup>1<\/sup>, J. Wong<sup>1<\/sup>, D. Knorr<sup>1<\/sup>, L. Blanchard<sup>2<\/sup>, J. C. Angulo-Lozano<sup>2<\/sup>, K. Whiting<sup>1<\/sup>, V. E. Seshan<sup>1<\/sup>, T. F. Donahue<sup>1<\/sup>, E. K. Cha<sup>1<\/sup>, A. C. Goh<sup>1<\/sup>, R. Smith<sup>1<\/sup>, G. Dalbagni<sup>1<\/sup>, C. Hernandez<sup>1<\/sup>, M. McCarter<sup>1<\/sup>, E. J. Pietzak<sup>1<\/sup>, J. E. Rosenberg<sup>1<\/sup>, J. V. Ravetch<sup>2<\/sup>, B. H. Bochner<sup>1<\/sup>; <br\/><sup>1<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>2<\/sup>The Rockefeller University, New York, NY","CSlideId":"","ControlKey":"ab420c04-b47b-4def-b643-e379315b8a60","ControlNumber":"9822","DisclosureBlock":"&nbsp;<b>J. C. Osorio, <\/b> None..<br><b>M. Alam, <\/b> None.&nbsp;<br><b>J. Wong, <\/b> <br><b>Genentech<\/b> Employment. <br><b>D. Knorr, <\/b> <br><b>Regeneron<\/b> Employment.<br><b>L. Blanchard, <\/b> None..<br><b>J. C. Angulo-Lozano, <\/b> None..<br><b>K. Whiting, <\/b> None..<br><b>V. E. Seshan, <\/b> None..<br><b>T. F. Donahue, <\/b> None..<br><b>E. K. Cha, <\/b> None..<br><b>A. C. Goh, <\/b> None..<br><b>R. Smith, <\/b> None..<br><b>G. Dalbagni, <\/b> None..<br><b>C. Hernandez, <\/b> None..<br><b>M. McCarter, <\/b> None..<br><b>E. J. Pietzak, <\/b> None..<br><b>J. E. Rosenberg, <\/b> None.&nbsp;<br><b>J. V. Ravetch, <\/b> <br><b>Inventor on patents covering 2141-V11<\/b> Other. <br><b>B. H. Bochner, <\/b> <br><b>Olympus<\/b> Other, Lecturer.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11612","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT086","PresenterBiography":"","PresenterDisplayName":"Juan Osorio, MD","PresenterKey":"b3ec6694-b803-434c-8f52-b028bf0ded2d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT086. Phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Phosphatidylinositol 3-kinase (PI3K),mTOR,Pathway,Prostate cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"A. Sharp<sup>1<\/sup>, A. Bernard-Tessier<sup>2<\/sup>, D. Borchiellini<sup>3<\/sup>, J. de Bono<sup>1<\/sup>, K. Fizazi<sup>2<\/sup>, G. Gravis<sup>4<\/sup>, D. Lorente<sup>5<\/sup>, H. Mahammedi<sup>6<\/sup>, B. Mellado<sup>7<\/sup>, D. Olmos<sup>8<\/sup>, S. Pacey<sup>9<\/sup>, J. Piulats<sup>10<\/sup>, S. P. Ramirez<sup>11<\/sup>, <b>I. Gorbatchevsky<\/b><sup>12<\/sup>, E. Heath<sup>13<\/sup>; <br\/><sup>1<\/sup>Institute of Cancer Research, London, United Kingdom, <sup>2<\/sup>Gustave Roussy, Paris, France, <sup>3<\/sup>Centre Antoine Lacassagne, Nice, France, <sup>4<\/sup>Institut Paoli-Calmettes, Marseille, France, <sup>5<\/sup>Instituto Valenciano de Oncologa, Valencia, Spain, <sup>6<\/sup>Centre Jean Perrin, Clermont-Ferrand, France, <sup>7<\/sup>Hospital Clinic Barcelona, Barcelona, Spain, <sup>8<\/sup>Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>9<\/sup>University of Cambridge, Cambridge, United Kingdom, <sup>10<\/sup>Institut Catala d'Oncologia, Barcelona, Spain, <sup>11<\/sup>Hospital General Universitario Gregorio Maranon, Madrid, Spain, <sup>12<\/sup>Celcuity, Minneapolis, MN, <sup>13<\/sup>Karmanos Cancer Institute, Detroit, MI","CSlideId":"","ControlKey":"10cc382b-3a89-43c1-9bdc-00ca21e586c8","ControlNumber":"9945","DisclosureBlock":"<b>&nbsp;A. Sharp, <\/b> <br><b>Sanofi; Roche-Genentech; Nurix<\/b> Travel. <br><b>Astellas; Merck Sharp & Dohme<\/b> Other, Speaker honoraria. <br><b>DE Shaw Research; CHARM Therapeutics; Ellipses; Droia<\/b> Other, Advisor. <br><b>ICR<\/b> Other, ICR has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K\/AKT pathway inhibitors (no personal income).&nbsp;<br><b>A. Bernard-Tessier, <\/b> <br><b>Novartis; Janssen; MSD; AstraZeneca; Roche; Astellas; Bayer; Orion<\/b> Other, Speaker, advisor. <br><b>D. Borchiellini, <\/b> <br><b>Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck; MSD Oncology; Pfizer<\/b> Other, Advisor. <br><b>Bayer; Bristol-Myers Squibb; Ipsen; Janssen; MSD Oncology; Pfizer<\/b> Travel. <br><b>Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Taiho<\/b> Grant\/Contract. <br><b>J. de Bono, <\/b> <br><b>AstraZeneca; Sanofi; Astellas Pharma; Pfizer; Genentech; Janssen Oncology; Daiichi Sankyo; Amgen; Bayer; GSK; Merck Serono; MSD; ImCheck<\/b> Other, Honoraria. <br><b>AstraZeneca; Sanofi; Genentech; Astellas; Bayer; Pfizer; MSD; Merck Serono; Daiichi Sankyo; Janssen Oncology; GSK; Amgen, Sanofi; ImCheck; AstraZeneca; Novartis<\/b> Other, Advisor. <br><b>AstraZeneca<\/b> Other, Speaker. <br><b>AstraZeneca; Astellas; GlaxoSmithKline; Orion Pharma; Sanofi; Genmab; Taiho; QIAGEN; Vertex Pharmaceuticals<\/b> Travel. <br><b>Institution<\/b> Patent, Other Intellectual Property, Abiraterone Rewards to Inventors (Inst), PARP inhibitors and DNA repair defects (Inst), Targeting of IL-23 in prostate cancer (Inst), CHK1 inhibitor (Inst). <br><b>AstraZeneca (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Daiichi Sankyo (Inst), Merck Serono (Inst), Astex Pharmaceuticals (Inst), Merck Sharp & Dohme (Inst), CellCentric (Inst), Bayer (Inst),<\/b> Grant\/Contract. <br><b>Amgen (Inst), Astellas Pharma (Inst), Harpoon (Inst), Janssen (Inst), Pfizer (Inst), Genentech\/Roche (Inst), Sanofi Aventis GmbH (Inst)<\/b> Grant\/Contract. <br><b>K. Fizazi, <\/b> <br><b>Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)<\/b> Other, Honoraria. <br><b>Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst)<\/b> Other, Advisor. <br><b>Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)<\/b> Other, Advisor. <br><b>AstraZeneca; Janssen; MSD; Pfizer<\/b> Travel. <br><b>G. Gravis, <\/b> <br><b>Amgen (Inst); Bayer (Inst); BMS (Inst); Curium Pharma (Inst); Janssen (Inst); Merck\/Pfizer (Inst)<\/b> Other, Advisor. <br><b>Advanced Accelerator Applications (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); Pfizer\/EMD Serono (Inst)<\/b> Other, Speaker. <br><b>BMS (Inst)<\/b> Grant\/Contract. <br><b>BAYER (Inst); Pfizer\/EMD Serono (Inst)<\/b> Other, Expert Testimony. <br><b>AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Pfizer<\/b> Travel. <br><b>D. Lorente, <\/b> <br><b>AstraZeneca; Bristol-Meyers; Janssen Oncology; Pfizer<\/b> Other, Advisor. <br><b>Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers; Janssen Oncology; Merck\/Pfizer; Merck\/Pfizer; Pfizer; Roche<\/b> Other, Speaker. <br><b>Astellas Pharma; AstraZeneca; Janssen Oncology<\/b> Travel. <br><b>H. Mahammedi, <\/b> <br><b>Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS; Janssen-Cilag; MSD Oncology; Novartis; Pfizer<\/b> Other, Honoraria. <br><b>Bayer; BMS<\/b> Other, Advisor. <br><b>Janssen-Cilag; Pfizer<\/b> Travel.<br><b>B. Mellado, <\/b> None.&nbsp;<br><b>D. Olmos, <\/b> <br><b>Astellas Pharma (Inst); Bayer; Janssen<\/b> Other, Honoraria. <br><b>AstraZeneca (Inst); Bayer; Bayer (Inst); Clovis Oncology; Daiichi Sankyo; Janssen; Janssen (Inst); MSD Oncology<\/b> Advisor. <br><b>Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech\/Roche (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst)<\/b> Grant\/Contract. <br><b>Astellas Pharma; AstraZeneca Spain; Bayer; Ipsen; Janssen; Roche<\/b> Travel. <br><b>S. Pacey, <\/b> <br><b>Astra Zeneca; Janssen; Guardant Health<\/b> Grant\/Contract. <br><b>J. Piulats, <\/b> <br><b>Janssen Oncology; Astellas; VCN Biosciences; Clovis; Roche\/Genentech; BMS; MSD; BeiGene<\/b> Other, Advisor. <br><b>BMS; AstraZeneca\/MedImmune; MSD; Pfizer\/EMD Serono; Incyte; Janssen<\/b> Grant\/Contract. <br><b>Janssen Oncology; Roche; BMS<\/b> Travel. <br><b>S. P. Ramirez, <\/b> <br><b>GSK-Tesaro; PharmaMar<\/b> Other, Advisor. <br><b>Roche; GSK-Tesaro<\/b> Other, Speaker. <br><b>Roche; GSK-Tesaro; AstraZeneca-MS<\/b> Travel. <br><b>I. Gorbatchevsky, <\/b> <br><b>Celcuity<\/b> Employment, Stock. <br><b>E. Heath, <\/b> <br><b>Astellas Pharma; AstraZeneca; Bayer; Caris Life Sciences; Genzyme; Janssen; Johnson & Johnson\/Janssen; Sanofi; Seagen<\/b> Other, Honoraria. <br><b>Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Sanofi; Seagen<\/b> Other, Advisor. <br><b>Sanofi<\/b> Other, Speaker. <br><b>Agensys (Inst); AIQ Solutions (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); BMS<\/b> Grant\/Contract. <br><b>Calibr (Inst); Calithera Bio(Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curemeta<\/b> Grant\/Contract. <br><b>Daiichi Sankyo(Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech\/Roche (Inst); Gilead<\/b> Grant\/Contract. <br><b>GSK(Inst); Harpoon(Inst); Ignyta (Inst); Infinity; (Inst); Inovio(Inst); ITeos;(Inst); Janssen(Inst)<\/b> Grant\/Contract. <br><b>Medivation (Inst); Merck (Inst); MSD(Inst); Millennium (Inst); Mirati(Inst); Modraceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst);<\/b> Grant\/Contract. <br><b>Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); POINT Biopharma (Inst); Roche (Inst)<\/b> Grant\/Contract. <br><b>Seagen (Inst); Synta (Inst); Tokai (Inst); Zenith Epigenetics (Inst)<\/b> Grant\/Contract. <br><b>Caris Life Sciences<\/b> Travel.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11613","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT087","PresenterBiography":null,"PresenterDisplayName":"Igor Gorbatchevsky, MD","PresenterKey":"eb2ea5f8-4ce3-4fee-99dc-df6eebb4302d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT087. A phase 1\/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1\/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Antiangiogenic therapy,Small molecule inhibitor,selective,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"C. Gomez-Roca<sup>1<\/sup>, P. Cassier<sup>2<\/sup>, M. Fitzgerald<sup>3<\/sup>, L. Davenne<sup>4<\/sup>, C. Costantin<sup>5<\/sup>, P. Rochaix<sup>1<\/sup>, J.-P. Delord<sup>1<\/sup>, J. Friend<sup>3<\/sup>, A. Nizzardo<sup>5<\/sup>, A. Tagliavini<sup>5<\/sup>, M. Pergher<sup>5<\/sup>, <b>P. Fons<\/b><sup>4<\/sup>, M. Mandron<sup>4<\/sup>; <br\/><sup>1<\/sup>Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France, <sup>2<\/sup>Centre Lon Brard, Lyon, France, <sup>3<\/sup>Kazia Therapeutics, Sydney, Australia, <sup>4<\/sup>Evotec International GmbH, Toulouse, France, <sup>5<\/sup>Evotec International GmbH, Verona, Italy","CSlideId":"","ControlKey":"9a0de05d-c355-4936-84f6-a39cc41106fa","ControlNumber":"9717","DisclosureBlock":"<b>&nbsp;C. Gomez-Roca, <\/b> <br><b>Bristol Myer Squibb<\/b> Grant\/Contract. <br><b>Eisai<\/b> Grant\/Contract. <br><b>Pierre Fabre<\/b> Grant\/Contract. <br><b>Roche\/genentech<\/b> Grant\/Contract. <br><b>Roche\/genentech<\/b> Grant\/Contract. <br><b>P. Cassier, <\/b> <br><b>Novartis<\/b> Grant\/Contract, Travel. <br><b>Roche\/Genentech<\/b> Grant\/Contract, Travel. <br><b>Amgen<\/b> Grant\/Contract, Travel. <br><b>Astra Zeneca<\/b> Grant\/Contract. <br><b>Merck Serono<\/b> Grant\/Contract. <br><b>Lilly<\/b> Grant\/Contract. <br><b>Blueprint medicines<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract, Travel. <br><b>celgene<\/b> Grant\/Contract. <br><b>plexxikon<\/b> Grant\/Contract. <br><b>Abbvie<\/b> Grant\/Contract. <br><b>Bristol-Myers Squibb<\/b> Grant\/Contract, Travel. <br><b>Merck Serono<\/b> Grant\/Contract, Travel. <br><b>Merck Sharp and Dome<\/b> Grant\/Contract, Travel. <br><b>Taiho pharmaceuticals<\/b> Grant\/Contract. <br><b>M. Fitzgerald, <\/b> <br><b>Kazia Therapeutics<\/b> Employment. <br><b>L. Davenne, <\/b> <br><b>Evotec International GmbH<\/b> Employment. <br><b>C. Costantin, <\/b> <br><b>Evotec International GmbH<\/b> Employment.<br><b>P. Rochaix, <\/b> None.&nbsp;<br><b>J. Delord, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Merck Serono<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>Pierre Fabre<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Astra Zeneca<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Transgene<\/b> Grant\/Contract. <br><b>J. Friend, <\/b> <br><b>Kazia Therapeutics<\/b> Employment. <br><b>A. Nizzardo, <\/b> <br><b>Evotec International GmbH<\/b> Employment. <br><b>A. Tagliavini, <\/b> <br><b>Evotec International GmbH<\/b> Employment. <br><b>M. Pergher, <\/b> <br><b>Evotec International GmbH<\/b> Employment. <br><b>P. Fons, <\/b> <br><b>Evotec<\/b> Employment. <br><b>M. Mandron, <\/b> <br><b>Evotec International GmbH<\/b> Employment.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11614","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT088","PresenterBiography":null,"PresenterDisplayName":"Pierre Fons, PhD","PresenterKey":"85eae16b-0aaf-42a7-95e1-9a128b8d32ae","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT088. EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study<b><\/b><b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study<b><\/b><b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Small molecule inhibitor,Kinase inhibitors,Solid tumors,Drug resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J.-S. Chen<sup>1<\/sup>, M.-H. Chen<sup>2<\/sup>, Y.-C. Liu<sup>3<\/sup>, W.-C. Chou<sup>1<\/sup>, N.-J. Chiang<sup>2<\/sup>, H.-C. Wang<sup>3<\/sup>, T.-S. Yeh<sup>4<\/sup>, S.-F. Cho<sup>3<\/sup>, C.-H. Wang<sup>5<\/sup>, <b>I.-F. Lee<\/b><sup>6<\/sup>, L.-T. Chen<sup>3<\/sup>; <br\/><sup>1<\/sup>Department of Hematology-Oncology, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan, <sup>2<\/sup>Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan, <sup>3<\/sup>Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan, <sup>4<\/sup>Department of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan, <sup>5<\/sup>Division of Hematology-Oncology, Keelung Chang Gung Memorial Hospital, Keelung City, Taiwan, <sup>6<\/sup>Taivex Therapeutics Corporation, Taipei City, Taiwan","CSlideId":"","ControlKey":"29afcf88-75a3-4813-ae8e-14390bcc2798","ControlNumber":"9778","DisclosureBlock":"&nbsp;<b>J. Chen, <\/b> None..<br><b>M. Chen, <\/b> None..<br><b>Y. Liu, <\/b> None..<br><b>W. Chou, <\/b> None..<br><b>N. Chiang, <\/b> None..<br><b>H. Wang, <\/b> None..<br><b>T. Yeh, <\/b> None..<br><b>S. Cho, <\/b> None.&nbsp;<br><b>C. Wang, <\/b> <br><b>Taivex Therapeutics Corporation; NatureWise Biotech & Medicals Corporation; Efficient Pharma Management Corporation<\/b> Other, Consultancy. <br><b>I. Lee, <\/b> <br><b>Taivex Therapeutics Corporation<\/b> Employment. <br><b>L. Chen, <\/b> <br><b>PharmaEngine; Taivex; OBI<\/b> Other, Honoraria. <br><b>ONO; BMS; Eli Lilly; MSD; Ipsen; TTY; SynCore; Novartis; AstraZeneca; CStone; Astellas; Taivex<\/b> Other, Advisory\/Consultancy. <br><b>SynCore; TTY; Polaris; ACT Genomics; Pfizer; BMS; Novartis; Merck Serono<\/b> Grant\/Contract. <br><b>HuniLife, Taiwan<\/b> Other, Royalties. <br><b>ScinoPharm Taiwan, Ltd.<\/b> Other, Board of Directors.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11615","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT089","PresenterBiography":null,"PresenterDisplayName":"I-Fang Lee, MS","PresenterKey":"b919a35b-b245-4766-a9dd-d9c59d01812c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT089. A phase 1 multi-center, open label, dose escalation study to evaluate the safety, pharmacokinetics (PK) and anti-tumor activity of T-1301, a novel small molecular multi-target kinase inhibitor, in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1 multi-center, open label, dose escalation study to evaluate the safety, pharmacokinetics (PK) and anti-tumor activity of T-1301, a novel small molecular multi-target kinase inhibitor, in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I clinical trials in progress,,"},{"Key":"Keywords","Value":"Targeted therapy,NEC,T cell engager,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Capdevila<sup>1<\/sup>, T. Vandamme<sup>2<\/sup>, P. Niccoli<sup>3<\/sup>, S. Mishima<sup>4<\/sup>, K. Kato<sup>5<\/sup>, Y. Ma<sup>6<\/sup>, <b>P. Sun<\/b><sup>7<\/sup>, L. Geng<sup>8<\/sup>, U. M. Lauer<sup>9<\/sup>; <br\/><sup>1<\/sup>Department of Medical Oncology, Vall dHebron University Hospital and Vall dHebron Institute of Oncology (VHIO), Barcelona, Spain, <sup>2<\/sup>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Department of Oncology, Antwerp University Hospital, Antwerp, Belgium, <sup>3<\/sup>Institut Paoli-Calmettes, Department of Oncology, Marseille, France, <sup>4<\/sup>Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, <sup>5<\/sup>Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, <sup>6<\/sup>Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, <sup>7<\/sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, <sup>8<\/sup>Boehringer Ingelheim (China) Investment Co., Ltd., Shanghai, China, <sup>9<\/sup>Department of Medical Oncology & Pneumology, University Hospital Tbingen, Tbingen, Germany","CSlideId":"","ControlKey":"5c40bf3c-14a0-4e05-b57d-b2a0505c518f","ControlNumber":"10472","DisclosureBlock":"<b>&nbsp;J. Capdevila, <\/b> <br><b>IPSEN<\/b> Grant\/Contract, Other, Support for the present manuscript\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Astrazeneca<\/b> Grant\/Contract. <br><b>Advanced Accelerator Applications-Novartis<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract, Other, Payment\/Honoraria. <br><b>Eisai<\/b> Grant\/Contract, Other, Payment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Pfizer<\/b> Grant\/Contract, Other, Payment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Novartis<\/b> Grant\/Contract, Other, Payment\/Honoraria. <br><b>Esteve<\/b> Other, Payment\/Honoraria. <br><b>Huchison MediPharma<\/b> Other, Payment\/Honoraria. <br><b>Isotopen Technologien<\/b> Other, Payment\/Honoraria. <br><b>Lilly<\/b> Other, Payment\/Honoraria. <br><b>Merck Serono<\/b> Other, Payment\/Honoraria. <br><b>Sanofi<\/b> Other, Payment\/Honoraria.<br><b>T. Vandamme, <\/b> None..<br><b>P. Niccoli, <\/b> None.&nbsp;<br><b>S. Mishima, <\/b> <br><b>Eli Lilly<\/b> Other, honoraria for lectures. <br><b>Taiho<\/b> Other, honoraria for lectures. <br><b>Merck Seronobiopharma<\/b> Other, honoraria for lectures. <br><b>Roche Diagnostics<\/b> Other, honoraria for lectures. <br><b>Chugai<\/b> Other, honoraria for lectures. <br><b>K. Kato, <\/b> <br><b>ONO<\/b> Other, Consulting fees\u000d\u000aPayment\/honoraria\u000d\u000aPayment for expert testimony. <br><b>Bristol Myers Squibb<\/b> Other, Consulting fees\u000d\u000aPayment\/honoraria\u000d\u000aPayment for expert testimony. <br><b>Beigene\/ Novartis<\/b> Other, Consulting fees. <br><b>Astrazeneca<\/b> Other, Consulting fees. <br><b>Roche<\/b> Other, Consulting fees. <br><b>BAYER<\/b> Other, Consulting fees. <br><b>Merck & Co.<\/b> Other, Consulting fees. <br><b>Merck bio<\/b> Other, Consulting fees. <br><b>Janssen<\/b> Other, Consulting fees. <br><b>Y. Ma, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>P. Sun, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>L. Geng, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>U. M. Lauer, <\/b> <br><b>Boehringer Ingelheim Pharma GmbH & Co<\/b> Grant\/Contract, Other, Consultant\u000d\u000aInvestigator Agreements. <br><b>Boehringer Ingelheim International GmbH<\/b> Other, Consultant. <br><b>Novartis Radiopharmaceuticals GmbH<\/b> Other, Advisory Boards. <br><b>Asgard Therapeutics<\/b> Other, Advisory Boards. <br><b>Abalos Therapeutics<\/b> Other, Advisory Boards.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11616","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT090","PresenterBiography":null,"PresenterDisplayName":"Ping Sun, Unknown","PresenterKey":"2a7af8fa-a8c4-472f-8028-2ccd7d8ef65f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT090. DAREON&#8482;-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"619","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials in Progress 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"DAREON&#8482;-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas","Topics":null,"cSlideId":""}]